CodexisLTS:0I0X -5.07%63 Days Payable is 81.37 as of Mar. 2026, which is 10% below its 10-year median of 90.61. GuruFocus rates LTS:0I0X with a GF Score™ of 63/100 and a GF Value™ of $2.53 (Fairly Valued). The stock has 6 warning signs investors should review. Among 701 Biotechnology companies, Codexis ranks better than 50.64% on this metric.
Codexis's average Accounts Payable for the
three
months ended in Mar. 2026 was $1.84 Mil. Codexis's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $2.06 Mil.
Hence, Codexis's Days Payable for the
three
months ended in Mar. 2026 was 81.37.
The historical rank and industry rank for Codexis's Days Payable or its related term are showing as below:
LTS:0I0X'
s Days Payable Range Over the Past 10 Years
Min: 29.95 Med: 90.61 Max: 142.79
Current: 114.68
During the past 13 years, Codexis's highest Days Payable was 142.79. The lowest was 29.95. And the median was 90.61.
LTS:0I0X's Days Payable is ranked better than 50.64% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs LTS:0I0X: 114.68
Codexis's Days Payable
declined
from Mar. 2025 (148.36) to Mar. 2026 (81.37).
It may suggest that Codexisaccelerated paying its suppliers.
Codexis Days Payable Related Terms
Codexis Days Payable Historical Data
* Premium members only.
The historical data trend for Codexis's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0I0X vs KROS, CAMP, VYGR: Days Payable Comparison
For the Biotechnology subindustry, Codexis's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Codexis Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Codexis's Days Payable distribution charts can be found below:
* The bar in red indicates where Codexis's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Codexis's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Codexis (LTS:0I0X) has a Days Payable of 81.37 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Codexis and its competitors. This is 10% below median its historical median of 90.61. Over the past decade, Codexis' Days Payable has ranged from 29.95 to 142.79. According to the industry distribution chart, Codexis ranks #346 out of 701 companies in the Biotechnology industry, placing it in the top 49.4%.
Is Codexis' Days Payable too high?
Codexis' current Days Payable of 81.37 is 10% below median its 10-year median of 90.61. Over the past 10 years, this metric has ranged from a low of 29.95 to a high of 142.79. The Biotechnology industry median Days Payable is 112.84. Codexis' value of 81.37 is 27.9% below this industry median. Based on the distribution chart, Codexis ranks #346 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Codexis has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Codexis' Days Payable compare to KROS and CAMP?
According to the Biotechnology industry distribution chart, Codexis ranks #346 out of 701 companies for Days Payable. This puts Codexis in the upper half of its industry. The industry median Days Payable is 112.84. Codexis' value of 81.37 is 27.9% below this benchmark. Historically, Codexis' own Days Payable has ranged from 29.95 to 142.79 over the past decade. While the company's 10-year median is 90.61 vs. the industry median of 112.84, Codexis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Codexis's current Days Payable of 81.37 is 27.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Codexis and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Codexis's current Days Payable is 81.37, which is 10% below median its own 10-year median of 90.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Codexis stock overvalued right now?
Based on GuruFocus' analysis, Codexis (LTS:0I0X) is currently considered Fairly Valued. The stock's GF Value™ is $2.53, compared to a current price of $2.44 — trading 3.8% below its estimated fair value. The current Days Payable is 81.37, which is 10% below median its 10-year median of 90.61 and 27.9% below the Biotechnology industry median of 112.84. Codexis' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Codexis (LTS:0I0X), the current Days Payable is 81.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Codexis (LTS:0I0X) Overvalued in 2026?
Based on GuruFocus' analysis, Codexis stock appears to be undervalued.
The current stock price of $2.44 is trading 3.8% below its estimated GF Value™ of $2.53.
GuruFocus considers Codexis to be Fairly Valued.
Key valuation signals for LTS:0I0X:
Days Payable: 81.37 (10% below median its 10-year median of 90.61)
GF Value™: $2.53 vs. price of $2.44 (3.8% below fair value)
Industry Position: 27.9% below the Biotechnology median (#346 of 701)
No single metric tells the full story. See the LTS:0I0X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
63GF Score
Get the complete analysis for LTS:0I0X
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0I0X has been successfully added to your 
